临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
3期
405-407,408
,共4页
非小细胞肺癌%靶向治疗%多西他赛%疗效%毒副作用
非小細胞肺癌%靶嚮治療%多西他賽%療效%毒副作用
비소세포폐암%파향치료%다서타새%료효%독부작용
non-small cell lung cancer%target therapy%docetaxel%therapeutic effect%toxicities
目的：探讨多西他赛单药或联合顺铂在分子靶向治疗失败的非小细胞肺癌中治疗疗效和安全性。方法32例非小细胞肺癌患者，曾接受过分子靶向治疗(吉非替尼或厄洛替尼)，靶向治疗后出现疾病进展，随机分成多西他赛单药组和多西他赛联合顺铂组，单药组13例，联合组19例。比较两组近期疗效、毒副作用及活动状况改善情况。结果多西他赛单药组有效率( CR+PR)23．1%，疾病控制率( CR+PR+NC)61．5%，多西他赛联合顺铂组，有效率26．3%，疾病控制率68．4%，两组有效率、疾病控制率相当，差异无统计学差异(P>0．05)；两组毒副反应，联合组的恶性呕吐、白细胞下降发生率明显高于单药组，有统计学差异(P<0．05)；活动状况改善率分别为84．6%和31．6%，单药组的活动状况改善率明显较高，与对照组相比差异有显著性(P<0．05)。结论多西他赛单药和多西他赛联合顺铂均是分子靶向治疗失败后可以选择的方案，都可以取得一定的治疗效果，其中单药组毒副作用较小。
目的：探討多西他賽單藥或聯閤順鉑在分子靶嚮治療失敗的非小細胞肺癌中治療療效和安全性。方法32例非小細胞肺癌患者，曾接受過分子靶嚮治療(吉非替尼或阨洛替尼)，靶嚮治療後齣現疾病進展，隨機分成多西他賽單藥組和多西他賽聯閤順鉑組，單藥組13例，聯閤組19例。比較兩組近期療效、毒副作用及活動狀況改善情況。結果多西他賽單藥組有效率( CR+PR)23．1%，疾病控製率( CR+PR+NC)61．5%，多西他賽聯閤順鉑組，有效率26．3%，疾病控製率68．4%，兩組有效率、疾病控製率相噹，差異無統計學差異(P>0．05)；兩組毒副反應，聯閤組的噁性嘔吐、白細胞下降髮生率明顯高于單藥組，有統計學差異(P<0．05)；活動狀況改善率分彆為84．6%和31．6%，單藥組的活動狀況改善率明顯較高，與對照組相比差異有顯著性(P<0．05)。結論多西他賽單藥和多西他賽聯閤順鉑均是分子靶嚮治療失敗後可以選擇的方案，都可以取得一定的治療效果，其中單藥組毒副作用較小。
목적：탐토다서타새단약혹연합순박재분자파향치료실패적비소세포폐암중치료료효화안전성。방법32례비소세포폐암환자，증접수과분자파향치료(길비체니혹액락체니)，파향치료후출현질병진전，수궤분성다서타새단약조화다서타새연합순박조，단약조13례，연합조19례。비교량조근기료효、독부작용급활동상황개선정황。결과다서타새단약조유효솔( CR+PR)23．1%，질병공제솔( CR+PR+NC)61．5%，다서타새연합순박조，유효솔26．3%，질병공제솔68．4%，량조유효솔、질병공제솔상당，차이무통계학차이(P>0．05)；량조독부반응，연합조적악성구토、백세포하강발생솔명현고우단약조，유통계학차이(P<0．05)；활동상황개선솔분별위84．6%화31．6%，단약조적활동상황개선솔명현교고，여대조조상비차이유현저성(P<0．05)。결론다서타새단약화다서타새연합순박균시분자파향치료실패후가이선택적방안，도가이취득일정적치료효과，기중단약조독부작용교소。
Objective To investigate the effect and securiy of docetaxel monotherapy or in combination with cisplatin in the treatment of patients with non-small cell lung cancer after failure of molecular targeted therapy. Meth-ods 32 patients with non-small cell lung cancer, who were failed by targeted therapy ( Gefitinib or Erlotinib) , were divided into two group randomly. The monotherapy group was treated with docetaxel, and the combined group was treated with docetaxel and cisplatin. Their terapeutic efficacy, side effects and quality of life of the two groups were compared. Results The response rates ( CR+PR) were 23. 1% and 26. 3% in the monotherapy group and the combined group respectively, and the clinical benefit rates ( CR+PR+NC) were 61. 5% and 68. 4% in two groups respectively (P>0. 05). The incidence of toxicities was significantly higher in the combined group than in the mono-therapy group (P<0. 05). The improvement rate of performance score was 84. 6% and 31. 6% respectively (P<0. 05). Conclusion Docetaxel monotherapy or in combination with cisplatin are both effective in the treatment of patients with non-small cell lung cancer after failure of molecular targeted therapy, but docetaxel monotherapy has fe-wer side effects.
